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OBJECTIVES The purpose of this study was to determine the incidence and demographic characteristics of
patients experiencing cardiac rupture after thrombolytic and adjunctive anticoagulant therapy
and to identify possible associations between the mechanism of thrombin inhibition (indirect,
direct) and the intensity of systemic anticoagulation with its occurrence.
BACKGROUND Cardiac rupture is responsible for nearly 15% of all in-hospital deaths among patients with
myocardial infarction (MI) given thrombolytic agents. Little is known about specific patient-
and treatment-related risk factors.
METHODS Patients (n 5 3,759) with MI participating in the Thrombolysis and Thrombin Inhibition in
Myocardial Infarction 9A and B trials received intravenous thrombolytic therapy, aspirin and
either heparin (5,000 U bolus, 1,000 to 1,300 U/h infusion) or hirudin (0.1 to 0.6 mg/kg bolus,
0.1 to 0.2 mg/kg/h infusion) for at least 96 h. A diagnosis of cardiac rupture was made clinically
in patients with sudden electromechanical dissociation in the absence of preceding congestive
heart failure, slowly progressive hemodynamic compromise or malignant ventricular arrhythmias.
RESULTS A total of 65 rupture events (1.7%) were reported—all were fatal, and a majority occurred within 48 h
of treatment. Patients with cardiac rupture were older, of lower body weight and stature and more likely
to be female than those without rupture (all p , 0.001). By multivariable analysis, age .70 years (odds
ratio [OR] 3.77; 95% confidence interval [CI] 2.06, 6.91), female gender (OR 2.87; 95% CI 1.44, 5.73)
and prior angina (OR 1.82; 95% CI 1.05, 3.16) were independently associated with cardiac rupture.
Independent predictors of nonrupture death included age .70 years (OR 3.68; 95% CI 2.53, 5.35) and
prior MI (OR 2.14; 95%, CI 1.45, 3.17). There was no association between the type of thrombin
inhibition, the intensity of anticoagulation and cardiac rapture.
CONCLUSIONS Cardiac rupture following thrombolytic therapy tends to occur in older patients and may explain
the disproportionately high mortality rate among women in prior clinical trials. Unlike major
hemorrhagic complications, there is no evidence that the intensity of anticoagulation associated
with heparin or hirudin administration influences the occurrence of rupture. (J Am Coll Cardiol
1999;33:479–87) © 1999 by the American College of Cardiology
Cardiac rupture, most often involving the left ventricular
free wall and less frequently the interventricular septum,
papillary muscle, right ventricular free wall and atria, is a
well recognized complication of acute myocardial infarction
(MI) that is responsible for 10% to 15% of all in-hospital
deaths. Written descriptions of this predominately fatal
event can be traced back several centuries to William Harvey
(1647) (1), followed 200 years later by the landmark
observations of Malmsten (1861) (2), Winsor (1880) (3),
Steven (1884) (4) and Krumbhaar (1925) (5), who linked
the occurrence of cardiac rupture to occlusive coronary
arterial thrombosis, “softening” of the myocardium and, in a
majority of cases, recent MI.
The reperfusion era has heightened an existing interest in
cardiac rupture. From a recent evaluation of over 350,000
patients with MI, several observations were made (6). First,
the overall incidence of cardiac rupture, although decreased
From the *Cardiovascular Thrombosis Research Center, University of Massachu-
setts Medical School, Worcester, Massachusetts; †St. Luke’s/Roosevelt Hospital
Center, Columbia University, College of Physicians and Surgeons, New York, New
York; ‡Brigham and Women’s Hospital, Harvard Medical School, Boston, Massa-
chusetts; §TIMI Database and Coordinating Center, Veterans Administration
Medical Center, West Roxbury, Massachusetts. Presented, in part, at the American
College of Cardiology Meetings in Atlanta, Georgia, March 29–April 1, 1998.
Manuscript received April 28, 1998; revised manuscript received September 10,
1998, accepted October 22, 1998.
Journal of the American College of Cardiology Vol. 33, No. 2, 1999
© 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00
Published by Elsevier Science Inc. PII S0735-1097(98)00582-8
with thrombolytic administration, was responsible for a
greater proportion of in-hospital fatal events, particularly
early deaths, than in patients not given thrombolytic agents.
Second, and in contrast to the prereperfusion era (7–9),
most cardiac ruptures associated with thrombolytic therapy
occurred within 24 to 48 h of infarction rather than later
(days 3 to 5) in the hospital course.
Although the nonspecific protease, plasmin, by weaken-
ing the collagen-based supporting network in a zone of
extensive myocardial necrosis may be an important
biochemical/enzymatic contributor, the associated charac-
teristics of a “susceptible” myocardium are largely unknown
and the time sequence of cardiac rupture, being similar to
major hemorrhagic events, raises questions about the con-
tribution of baseline patient characteristics and systemic
features, including coagulation status. Indeed an association
between anticoagulant therapy, a common adjunct in cur-
rent thrombolytic strategies, and cardiac rupture has been
considered (6) but not examined in a large-scale clinical
trial.
The purpose of our study was to determine the overall
incidence and demographic characteristics of patients expe-
riencing cardiac rupture after thrombolytic and adjunctive
anticoagulant therapy and to investigate the association
between thrombin inhibition, with either heparin or hiru-
din, and the intensity of systemic anticoagulation with the
development of rupture.
METHODS
The Thrombolysis and Thrombin Inhibition in Myocardial
Infarction (TIMI) 9 A and B trials have been described in
detail previously (10,11). Briefly, to be eligible for enroll-
ment patients were required to have an episode of ischemic
discomfort lasting $30 min within the prior 12 h. Electro-
cardiographic abnormalities, including either $0.1 mV ST
segment elevation in two anatomically contiguous leads or a
new left bundle branch block were also required. Patients
were excluded from study participation if there were con-
traindications for thrombolytic therapy (prior stroke, active
bleeding, major surgery within 2 months, confirmed blood
pressure .180/110 mm Hg), or if they were ,21 years of
age, had a serum creatinine .2.0 mg/dl, were of child-
bearing potential, had cardiogenic shock or were therapeu-
tically anticoagulated (prothrombin time $14 s, activated
partial thromboplastin time $60 s).
All patients received thrombolytic therapy in the form of
either front-loaded, weight-adjusted tissue plasminogen
activator (tPA) (12) (maximum dose 100 mg) over 90 min
or streptokinase (1.5 million U over 60 min). The selection
of a thrombolytic agent was at the treating physician’s
discretion. Patients received 150 to 325 mg of aspirin
immediately and daily thereafter and were then randomized
to receive either heparin or hirudin. Other medications
including beta-adrenergic blocking agents, nitrates, calcium
channel blocking agents, and angiotensin-converting en-
zyme inhibitors were used at the discretion of the treating
physician.
Study drug was administered either before or within
60 min of thrombolysis and was continued for at least 96 h.
In TIMI 9A (10) patients received either hirudin
(0.6 mg/kg bolus, 0.2 mg/kg/h infusion) or heparin
(5,000 U bolus, 1,000 U/h for patients ,80 kg or 1,300 U/h
for patients $80 kg) titrated to a target activated partial
thromboplastin time (aPTT) of 60 to 90 s. Because the rates
of hemorrhage were higher than expected in both treatment
arms, randomization was suspended after 757 patients had
been enrolled (10). In TIMI 9B the hirudin and heparin
dosing was reconfigured as follows: heparin (5,000 U bolus,
followed by a continuous infusion of 1,000 U/h); hirudin
(0.1 mg/kg bolus, followed by a continuous infusion of
0.1 mg/kg/h). Neither the bolus nor the infusion of hirudin
was permitted to exceed 15 mg (or 15 mg/h). The target
aPTT was 55 to 85 s with dose adjustments made for both
study drugs according to a standardized nomogram. Sam-
ples were obtained at 12 and 24 h after treatment initiation
and daily thereafter for aPTT measurement. All measure-
ments were performed by either a hospital-based anticoag-
ulation laboratory or a point-of-care coagulation monitor
(CoaguChek Plus; Boehringer-Mannheim Corporation,
Indianapolis, IN). Consistency in the method of monitoring
was encouraged within the participating centers.
A diagnosis of cardiac rupture was made (by the on-site
investigator) at the time of death in patients with electro-
mechanical dissociation or sudden cardiac death in the
absence of preceding congestive heart failure, slowly pro-
gressive hemodynamic compromise or malignant ventricular
arrhythmias. All major efficacy and safety end points,
including serious adverse events, were reviewed and classi-
fied by the Morbidity and Mortality Classification Com-
mittee, which was unaware of treatment assignment.
Statistical methods. The frequency of cardiac rupture
events was analyzed using the chi-square statistical method.
Comparisons were then made between heparin- and
hirudin-treated patients. The time to rupture- and non–
rupture-related death was analyzed using survival analysis
methods.
A logistic regression analysis was used to test the rela-
tionship between cardiac rupture (and nonrupture death)
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
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and clinical variables or covariates (age, gender, height,
weight, past history of angina, MI or hypertension, time to
treatment, thrombolytic agent, anticoagulant [heparin or
hirudin], site of infarction, pretreatment blood pressure,
initial pulse, serial aPTT measurements, in-hospital proce-
dures and medications before treatment and during the
study drug infusion). For multivariable analyses, the signif-
icance of each regression variable was adjusted for other
variables used in the model.
RESULTS
Baseline characteristics. A total of 3,759 patients were
enrolled in the TIMI 9A and 9B studies. There were no
significant differences in age, cardiac risk factors, site of
infarction, prior MI, thrombolytic agent or time from symp-
tom onset to the treatment between patients allocated to
heparin and those allocated to hirudin. The assigned study
drug was received by 97.2% of patients randomized (9,10).
There were a total of 65 (1.7%) cardiac rupture events
reported in TIMI 9—all were fatal. Fifteen (1.9%) were
reported in TIMI 9A and 50 (1.6%) in TIMI 9B. Patients
with rupture were older, on average by 10 years, of lower
body weight and stature and more likely to be female than
patients without rupture (all p 5 0.001). They were also
more likely to have a history of hypertension, be nonsmok-
ers and receive treatment later. An anterior site of infarction
was documented more often than other sites in patients with
rupture, and although Q waves were present on the elec-
trocardiogram in a majority of cases, nearly one out of every
three patients did not develop Q waves prior to the event.
The admission heart rate was higher in patients who
subsequently experienced cardiac rupture; however, there
were no differences in the presenting systolic and diastolic
blood pressures. The prerandomization use of ACE inhib-
itors, aspirin, beta-blockers and either oral or intravenous
anticoagulants did not differ between patients with cardiac
rupture and those without rupture.
Table 1 summarizes the baseline characteristics for pa-
tients with cardiac rupture, those with death from non–
cardiac rupture-related causes and patients surviving to 30
days after infarction. Patients dying, whether from cardiac
rupture or another cause, were older, of lower body weight
and stature, received treatment later, experienced prior
angina, had a history of hypertension, were nonsmokers and
had a higher initial heart rate than patients surviving their
infarction. A majority of deaths (90%) occurred within the
first 5 days. Patients dying from non–rupture-related causes
when compared to survivors were more likely to be diabetic
and have experienced a prior MI. In addition, their initial
blood pressure (systolic and diastolic) was lower, and their
heart rate was higher.
A comparison of patients dying from rupture- and non–
rupture-related events identified female gender and shorter
stature as being particularly prevalent in the former. A multi-
variable linear regression analysis was performed to identify
potential predictors of cardiac rupture (Fig. 1). Age .70 years
(odds ratio [OR] 3.77; 95% confidence interval [CI] 2.06,
6.91), female gender (OR 2.87; 95% CI 1.44, 5.73) and prior
angina (OR 1.82; 95% CI 1.05, 3.16) were independently
associated with rupture. A separate analysis was performed to
determine the predictors of nonrupture death at 30 days (Fig.
2). Age .70 years (OR 3.68; 95% CI 2.53, 5.35), initial pulse
.100 beats per minute (OR 3.08; 95% CI 2.02, 4.70) and
prior MI (OR 2.14; 55% CI 1.45, 3.17) were independently
associated with death not related to cardiac rupture.
Timing of cardiac rupture. Patients with cardiac rupture
died earlier in the hospital course than patients dying from
non–rupture-related causes (median 1.5 [range 0 to 15] days
Table 1. Baseline Characteristics (TIMI 9A and TIMI 9B)
Variable
Cardiac
Rupture/EMD
(n 5 65)
Death Without
Cardiac
Rupture/EMD
(n 5 171)
Alive Without
Cardiac
Rupture
(n 5 3523)
p
Value*
p
Value†
p
Value‡
Age (yr) 70.9 6 1.1 70.6 6 0.8 59.8 6 0.2 0.986 0.0001 0.0001
Female gender 39 (60%) 65 (38%) 871 (25%) 0.003 0.0001 0.0001
Weight (kg) 71.8 6 1.7 74.6 6 1.2 79.8 6 0.3 0.297 0.0001 0.0001
Height (cm) 165.3 6 1.3 168.1 6 0.8 170.4 6 0.2 0.090 0.0001 0.0015
Time to treatment (h) 3.92 6 0.34 3.77 6 0.25 3.38 6 0.05 0.701 0.045 0.011
Prior angina 29 (45%) 58 (34%) 1004 (29%) 0.173 0.005 0.096
Prior MI 11 (17%) 51 (30%) 572 (16%) 0.047 0.863 0.0001
Hypertension 32 (49%) 93 (54%) 1188 (34%) 0.557 0.011 0.004
Diabetes mellitus 10 (15%) 39 (23%) 544 (15%) 0.280 1.000 0.013
Current smoker 18 (28%) 52 (30%) 1580 (45%) 0.749 0.010 0.001
Initial systolic BP 132.95 6 2.52 122.48 6 1.67 131.02 6 0.36 0.001 0.430 0.0001
Initial diastolic BP 78.98 6 1.70 74.52 6 1.08 78.21 6 0.23 0.018 0.541 0.0003
Initial pulse 80.05 6 1.80 84.39 6 1.58 75.53 6 0.27 0.171 0.015 0.0001
*Cardiac rupture/EMD versus death without cardiac rupture/EMD. †Cardiac rupture/EMD versus patients alive without cardiac rupture. ‡Death without cardiac rupture/EMD
versus patients alive without cardiac rupture.
BP 5 blood pressure (mm Hg); EMD 5 electromechanical dissociation; MI 5 myocardial infarction.
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versus 3.7 [range 0 to 27] days; p 5 0.0001). Cardiac
rupture was analyzed separately after dividing events into
those occurring within 24 h of treatment initiation and
those occurring after 24 h of treatment. There were no
significant differences in the timing of rupture based on
clinical features, initial clinical assessment, site of infarction,
thrombolytic agent, time to treatment, thrombin antagonist
(heparin, hirudin) or the combination of thrombolytic and
thrombin antagonist (data not shown).
A comparison of rupture events either within or after 24 h
of treatment according to medications received prior to
hospital admission identified a trend toward reduced pre-
hospital aspirin use among patients experiencing rupture
within 24 h (10%) as compared to those experiencing
rupture after 24 h (24%) (p 5 0.19); however, there were no
differences in the use of beta-blockers, ACE inhibitors,
nitrates or calcium channel blockers. In contrast, patients
experiencing early rupture (#24 h) were less likely to have
been given aspirin (84% vs. 97%; p 5 0.09), oral beta-
blockers (3.2% vs. 35.4%; p , 0.001) and ACE inhibitors
(6.5% vs. 18.5%; p 5 0.02) during the study drug infusion
compared to those experiencing rupture at a later time
(.24 h). Compared with patients who survived their MI,
patients experiencing cardiac rupture received beta-blockers,
ACE inhibitors or both less often during the 96-h study
drug infusion. The difference was most notable for patients
with cardiac rupture during the initial 24 h, in whom ACE
inhibitors and beta-blockers were administered to 6.5% and
3.2% of patients, respectively. From a total of 31 rupture
events that were recorded, no patient had received both an
ACE inhibitor and beta-blocker. Patients dying from any
cause (rupture and non–rupture related), were less likely to
have received a beta-blocker or an ACE inhibitor than those
surviving their infarction. By multivariable analysis ACE
inhibitor or beta-blocker use were inversely associated with
cardiac rupture (OR 0.27; 95% CI 0.16, 0.46; p , 0.001).
Figure 1. Multivariable analysis of patients experiencing cardiac rupture or electromechanical dissociation (EMD) identified age $70
years, female gender and prior angina as independent predictors of an in-hospital event.
Figure 2. Multivariable analysis of patients with non–rupture-related death. Female gender was not independently associated with
non–cardiac rupture death.
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Thrombin antagonist and intensity of anticoagulation.
Patients experiencing death from rupture- and non–rupture-
related causes based on randomization to either heparin or
hirudin are summarized in Table 2. There was no difference in
the overall incidence of cardiac rupture death between heparin-
and hirudin-treated patients. The intensity of anticoagulation,
as determined by the aPTT at 12 and 24 h, did not differ
between patients with cardiac rupture- and non–rupture-
related death. Similarly, the corresponding aPTT values at
baseline, 12 h, 24 h, 48 h and 72 h for patients with and those
without cardiac rupture did not differ (Fig. 3).
By multivariable analysis neither heparin, hirudin nor an
aPTT greater than 90 s at any time point was independently
associated with cardiac rupture.
DISCUSSION
Cardiac rupture is an early and predominantly fatal compli-
cation of acute MI that occurs in approximately 1% of
patients but is responsible for nearly 15% of all deaths.
Thrombolytic therapy accelerates the occurrence of rupture
to within 24 to 48 h of treatment. Despite an early
clustering of events that could potentially be interpreted as
representing a major bleeding complication, our study
including over 3,700 patients treated with thrombolytics,
aspirin and adjunctive thrombin antagonists failed to iden-
tify an association between cardiac rupture, the mechanism
of thrombin inhibition and the intensity of systemic anti-
coagulation. We were able to show, however, that cardiac
Table 2. Patients With In-Hospital Death According to Treatment Group
Heparin
Cardiac Rupture
Hirudin
Cardiac Rupture/EMD
p
Value*
p
Value†
p
Value‡Yes No Yes No
Age (yr)
n 27 41 22 60 0.07 0.94 0.84
Mean 72.8 6 9.03 68.6 6 9.51 70.0 6 9.08 69.8 6 11.56
Gender
Male 12 (44.4%) 26 (64.3%) 8 (36.4%) 37 (61.7%) 0.007 0.004 0.312
Composite aPTT (s)
Mean 47.4 6 20.25 53.5 6 23.60 46.9 6 21.28 51.1 6 22.98 0.305 0.561 0.921
Median 48.0 47.0 52.5
Range 20 to 82 24 to 102 18 to 110
*Compares heparin-treated patients with and without cardiac rupture. †Compares hirudin-treated patients with and without cardiac rupture. ‡Compares heparin- and
hirudin-treated patients with cardiac rupture.
aPTT 5 activated partial thromboplastin time, composite (12- and 24-h aPTT values); EMD 5 electromechanical dissociation.
Figure 3. Serial coagulation measurements (activated partial thromboplastin times [aPTT]) for patients with and without cardiac
rupture–related death and those surviving to hospital discharge. There were no differences in the intensity of anticoagulation at the 12-,
24-, 48- and 72-h sampling time points.
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rupture as a cause for early death is particularly common in
women and the elderly, providing a mechanistic basis for the
higher mortality among women with MI compared to men
that has been reported previously in large-scale thrombolytic
trials and registries. Lastly, our findings suggest that early
ACE inhibitor and/or beta-blocker administration may
reduce the occurrence of cardiac rupture after thrombolytic
therapy.
Early mortality and cardiac rupture in women. Several
investigative groups have reported higher mortality rates for
women compared to men with acute MI receiving throm-
bolytic therapy (13–19). In TIMI 2 (13), the 6-week
mortality was 9% for women and 4% for men (adjusted
relative risk 1.54). Overall, women were older and had a
greater prevalence of prior congestive heart failure, systemic
hypertension and diabetes mellitus than men suffering an
infarction. However, mortality was higher among women
than men in all age strata and persisted after adjustment for
differences in baseline characteristics. The National Registry
of Myocardial Infarction (NRMI-1) reported a higher
in-hospital mortality in women than in men (6.8 vs. 3.0%)
even after adjusting for age. Lower body weight (,70 kg)
was also independently associated with in-hospital mortality
(20).
Among 350,755 patients enrolled in NRMI-1, 122,243
received thrombolytic therapy. Although cardiogenic shock
(pump failure) was the most common cause of death,
cardiac rupture was responsible for 12.1% of deaths com-
pared to 6.1% in patients with MI not receiving thrombo-
lytic therapy. By multivariable analysis thrombolytic agents,
prior MI, advancing age and female gender were indepen-
dently associated with cardiac rupture (9). The Gruppo
Italiano per lo Studio della Streptochinasi nell’Infarcto
Miocardico-2 investigators also found a strong association
between female gender, increasing age and death due to
cardiac rupture (21). Patients greater than 70 years of age
who died and underwent autopsy (84 patients) were found
to have cardiac rupture nearly 90% of the time.
Our group is the first to provide data showing that the
increased risk of death for women experiencing MI may be
attributable to cardiac rupture. By multivariable analysis,
female gender was independently associated with rupture
death; however, it was not an independent predictor of
death due to non–rupture-related causes. The predisposi-
tion of women with MI who receive thrombolytic therapy to
early cardiac rupture may be attributable to a susceptible
collagen framework within the infarcted myocardium.
Plasmin-mediated collagen degradation (22–26) and early
metalloprotease activation (27), by weakening the support-
ive connective tissue matrix, undoubtedly contribute to the
process of rupture. Plasmin generation is increased among
patients of low body weight (even with weight-adjusted
dosing) (28) and the collagen matrix itself is thought to
differ between women and men (29), particularly with
advancing age (30).
Thrombin inhibition, intensity of anticoagulation and
cardiac rupture. Hemorrhagic infarction, defined grossly
as visible blood within the myocardium, is a pathologic
feature that coexists with areas of extensive coagulative
necrosis (the end product of severe, persistent ischemia
found commonly within the center of the infarct zone).
Although recognized by pathologists for decades, hemor-
rhagic infarction has become a more common occurrence
with the advent of thrombolytic therapy (31), and some
have suggested that cardiac rupture is the direct result of
myocardial hemorrhage extending through planes of ne-
crotic and nonnecrotic myocardium (32). If myocardial
hemorrhage is a prerequisite for cardiac rupture, the con-
comitant administration of anticoagulant therapy, particu-
larly in high doses, could have a facilitatory effect among
patients with transmural necrosis (33–43).
There is no evidence from either experimental models or
clinical trials that anticoagulation exerts a direct effect on the
myocardium after infarction (44). In our study of over 3,700
patients with acute MI given thrombolytics, aspirin and
adjunctive anticoagulant therapy we were unable to identify
an association between the mechanism of thrombin inhibi-
tion (indirect via antithrombin-mediated neutralization or
direct), intensity of anticoagulation and cardiac rupture. To
the best of our knowledge this is the first study in the
reperfusion era to investigate the potential effect of antico-
agulation on rupture events among patients receiving
thrombolytic therapy. Despite a clear association between
the intensity of anticoagulation and major hemorrhage as
reported in several clinical trials (45,46), we did not uncover
a similar relationship with cardiac rupture even with doses
of heparin and hirudin that lead to a marked increase of
bleeding events. Although several studies performed in the
prereperfusion era reached a different conclusion, most were
nonrandomized retrospective analyses, the level of antico-
agulation was excessive and poorly regulated by current
standards and the focus was on hemorrhagic pericardial
effusions rather than cardiac rupture (34,35,38,39). Thus,
we conclude that cardiac rupture, as a pathologic event
involving the myocardium, is not a hemorrhagic complica-
tion directly related to antithrombotic therapy.
Concomitant pharmacologic therapy and cardiac rup-
ture. In TIMI 9, patients experiencing early cardiac rupture
(within 24 h of treatment) were less likely to have received
oral beta-blockers and ACE inhibitors during the drug
infusion study period than patients who had late rupture.
Further, patients with rupture (at any time) were treated less
often with ACE inhibitors and beta-blockers than patients
who survived their infarction. Zones of extensive myocardial
necrosis are characterized by a marked reduction in collagen
fibers (22,26); a process that begins within hours of infarc-
tion (47). Early infarct expansion and thinning developing
within these areas predispose to both cardiac rupture, as an
early manifestation of extensive collagen loss, and chamber
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dilation with or without aneurysm formation, as a late
feature of a weakened collagen supportive framework.
Therapies to prevent early infarct expansion have focused
predominantly on ACE inhibitor use in various patient
subsets, including those with or without clinical signs and
symptoms of congestive heart failure (48,49) when started
within (50) or after (51,52) 24 h of infarction. Our findings
are consistent with those from a previously reported clinical
trial (50); however, confirmation of the apparent protective
role of ACE inhibitors in patients receiving thrombolytic
therapy will require further investigation. Whether women
(particularly those greater than 70 years of age) and men
derive similar or differing degrees of benefit must also be
studied. The impact of beta-blocker therapy will be more
difficult to elucidate with one early trial suggesting a
protective effect (53) and a more recent study (54) showing
no difference in the incidence of cardiac rupture between
patients given beta-blockers early versus those treated later.
Unfortunately, the small number of events in TIMI 9 does
not permit us to draw firm conclusions.
Study limitations. The diagnosis of cardiac rupture was
based on clinical rather than strict pathologic (necropsy)
findings. It is possible that the number of events was
overestimated; however, prior large-scale clinical trials with
autopsy-confirmed cases have shown that a clinical diagno-
sis of cardiac rupture can be accurate (55), particularly when
patients with evidence of early pump failure who subse-
quently experience electromechanical dissociation and death
are excluded (56). Our analyses focused on fatal cardiac
rupture, which is most often caused by disruption of the
myocardial free wall. Regardless, this potential limitation is
unlikely to have influenced comparative event rates between
treatment groups, varying levels of anticoagulation or gen-
ders.
The absence of standardized or normalized methods for
aPTT measurement is a limitation for all large-scale clinical
trials attempting to investigate an association between
coagulation status and clinical events. The method for
aPTT determination was kept constant within participating
centers, and a consistent formulation of porcine heparin was
used throughout the trial. The aPTT is a standard method
of coagulation monitoring in the United States and has been
proven to be a useful measure for predicting patients at
increased risk for hemorrhagic events (45,46). Accordingly,
we did not evaluate other laboratory measurements of
anticoagulation.
Cardiac rupture typically occurs within 24 to 48 h of
treatment; therefore, we may have excluded patients dying
before the initial aPTT measurement in whom high aPTT
values may have been achieved within the first few hours
after thrombolytic therapy and study drug administration. It
is also possible that early hemorrhagic events or excessive
levels of anticoagulation could have prompted a decrease or
“down-titration” of the study drug infusion, causing lower
aPTT values at subsequent time points prior to rupture.
Although it is likely that most fatal events occur suddenly,
it is possible that type I ruptures (small slit-like tears)
progress over several hours, making both the duration and
the intensity of anticoagulation important rather than one or
two isolated readings. These factors may have limited our
ability to determine the association between aPTT and
cardiac rupture but should not have influenced our analysis
comparing heparin and hirudin. It is likely that the overall
low cardiac rupture event rate in TIMI 9 limited our ability
to detect modest influences attributable to thrombin inhi-
bition and/or the intensity of anticoagulation.
The apparent protective effect derived from ACE inhib-
itors and oral beta-blockers also may have been influenced
by the time sequence of cardiac rupture. Patients experienc-
ing rupture within the initial 24 h had less time to have been
treated, and their rapid decline in hemodynamic status may
have influenced management decisions. The use of ACE
inhibitors and beta-blockers was not randomized, and
therefore firm conclusions should not be drawn.
Lastly, in our study, all reported ruptures were fatal. It is
possible that this led to an underestimation of the number of
events and the overall impact of anticoagulation (57).
Although cardiac rupture is predominantly fatal, clinicians
must remain aware that subacute cardiac rupture with
tamponade if diagnosed early is potentially treatable.
Conclusions. Women with MI who receive thrombolytic
therapy appear to be at increased risk for early cardiac
rupture, providing a mechanistic explanation for their
higher mortality when compared with men. Despite a
recognized association between adjunctive anticoagulant
therapy and hemorrhagic complications, the available evi-
dence suggests that thrombin inhibition and the overall
intensity of systemic anticoagulation do not directly influ-
ence the occurrence of rupture. The early protective effects
of ACE inhibitors and beta-blockers warrant further inves-
tigation.
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